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Abstract 
Non-coding RNAs are increasingly recognized not only as regulators of various 
biological functions but also as targets for a new generation of RNA therapeutics and 
biomarkers. We hereby review recent insights relating to non-coding RNAs including 
microRNAs (e.g. miR-126, miR-146a), long non-coding RNAs (e.g. MIR503HG, 
GATA6-AS, SMILR) and circular RNAs (e.g. cZNF292) and their role in vascular 
diseases. This includes identification and therapeutic use of hypoxia-regulated non-
coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth 
muscle cell signalling, age-related non-coding RNAs and non-coding RNAs involved 
in the regulation of mitochondrial biology and metabolic control. Finally, we discuss 
non-coding RNA species with biomarker potential.  
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Introduction  
Manifestations of vascular diseases are the leading causes of morbidity and mortality 
1. Endothelial dysfunction is a key initiator of vascular disease. Proliferation, migration 
and the phenotype switch of smooth muscle cells are further hallmarks of vascular 
disease. Inflammatory cells aggravate vascular disease by release of secreted 
growth factors and cytokines, as well as cell/cell interactions that perpetuate the 
response to injury.  Relatively recently, non-coding RNA has been discovered as new 
regulators of vascular function and angiogenesis. Non-coding RNAs include 
microRNAs (miRs, miRNAs, short non-coding RNAs of about 20nt length), long non-
coding RNAs (lncRNAs) (length of >200 nt) as well as circular RNAs, a specific 
subtype of lncRNAs that form circular structures 2 through back-splicing events. Here, 
we focus on recent new insights how non-coding RNAs constitute regulatory 
therapeutic targets and biomarkers in vascular disease, with a special focus on 
cardiac disease-associated factors (e.g. hypoxia, ageing, smooth muscle cell biology 
and metabolism). 
Hypoxia-regulated non-coding RNAs  
Hypoxia is a key trigger for angiogenic events and has a substantial impact on the 
non-coding transcriptome. Oxygen depletion alters endothelial expression of a wide 
range of lncRNAs, as indicated by next-generation RNA sequencing and microarray 
approaches in endothelial cells subjected to hypoxia 3.  Validation experiments 
confirmed strong hypoxia-dependent activation of 2 intergenic lncRNAs (LINC00323 
and MIR503HG). Silencing of these lncRNA transcripts led to angiogenic defects, 
including repression of growth factor signaling and/or the key endothelial transcription 
factor GATA2. Endothelial loss of these hypoxia-driven lncRNAs impaired cell-cycle 
control and inhibited capillary formation. The potential clinical importance of identified 
 CVR-2018-115  
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endothelial lncRNAs to vascular structural integrity was demonstrated in an ex vivo 
model of human induced pluripotent stem cell–based engineered heart tissue (EHT) 
showing that pharmacological inhibition of these lncNRAs impaired vascular structure 
appearance. Interestingly, research in the non-coding RNA field discovered the well-
known endothelial (and protein-coding RNA) transcription factor GATA2 as a 
common target for many non-coding RNAs 4. GATA2 orchestrates the expression of 
many endothelial-specific genes, illustrating its crucial importance for endothelial cell 
function 5. In addition to being regulated through the actions of endothelial lncRNAs 
LINC00323 and MIR503HG, GATA2 was recently identified to be also a master 
switch for several key microRNAs. Using profiling approaches, the GATA2-
dependent miR transcriptome was identified 6. Indeed, global miRNAnome-screening 
identified several GATA2-regulated miRNAs, including miR-126 and miR-221. 
Specifically, proangiogenic miR-126 was regulated by GATA2 transcriptionally and 
targeted antiangiogenic SPRED1 and FOXO3a contributing to GATA2-mediated 
formation of normal vascular structures, whereas GATA2 deficiency led to vascular 
abnormalities. In contrast to GATA2 deficiency, supplementation with miR-126 
normalized vascular function and expression profiles of cytokines contributing to 
proangiogenic paracrine effects. GATA2 silencing resulted in endothelial DNA 
hypomethylation leading to induced expression of antiangiogenic miR-221 by 
GATA2-dependent demethylation of a putative CpG island in the miR-221 promoter. 
Mechanistically, a reverted GATA2 phenotype by endogenous suppression of miR-
221 was mediated through direct proangiogenic miR-221 target genes ICAM1 and 
ETS1. Of therapeutic importance was the finding that in a mouse model of carotid 
injury with endothelial-specific repressed GATA2, systemic supplementation of miR-
126-coupled nanoparticles enhanced miR-126 availability in the carotid artery. MiR-
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126 improved reendothelialization of injured carotid arteries in vivo thus proving a 
therapeutic strategy for treatment of GATA2-deficient vascular diseases. 
An additional screen for hypoxia-regulated lncRNAs revealed that the long non-
coding antisense transcript of GATA6 (GATA6-AS) is induced by hypoxia in 
endothelial cells as well 7. Silencing of GATA6-AS in endothelial cells in vitro 
diminished TGF-β2-induced endothelial-mesenchymal transition. Transplantation of 
GATA6-AS modulated human umbilical vein endothelial cells (HUVECs) via 
application of an antisense oligonucleotide (GapmeR) promoted the formation of 
human blood vessels in immune deficient mice. Mechanistically, GATA6-AS 
interacted with the known deaminase LOXL2, which can remove activating H3K4me3 
chromatin marks, and controlled a set of angiogenesis-related genes that are 
inversely regulated by LOXL2 and GATA6-AS silencing. Specifically, GATA6-AS 
silencing reduces H3K4me3 methylation of two of these genes, periostin and 
cyclooxygenase-2, suggesting that GATA6-AS acts as negative regulator of nuclear 
LOXL2 function. Interestingly, - at least in endothelial cells in vitro - the levels of 
secreted LoxL2, which are known to regulate collagen cross-linking and are 
implicated in cardiac fibrosis 8, were not affected.  
Non-coding RNAs are also molecular targets in therapeutic revascularization. It was 
recently demonstrated that endothelial cells can be derived via both directed 
differentiation and haematopoetic origin 9. Expression of the lncRNA SENCR, a 
lncRNA already known to be expressed in vascular SMCs, 10 was upregulated upon 
differentiation to endothelial cells, and manipulation of SENCR during differentiation 
affected endothelial cell appearance. Interestingly, SENCR modulation modified the 
angiogenic phenotype of endothelial cells, suggesting that lncRNAs have important 
regulatory functions for vascular cell types. Such studies are consistent with others in 
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the field, assessing different lncRNA in endothelial cells 11-13. Circulating levels of 
SENCR are also an independent predictor of diastolic function and remodeling in 
patients with type 2 diabetes 14.  
Apart from linear lncRNAs, circular forms of RNA species exist and are differentially 
regulated in the context of cardiovascular diseases 2, 15. CircRNAs lack 
polyadenylation, are resistant to RNase R digestion and localized to the cytoplasm. 
Boeckel et al explored the expression and function of circular RNAs in endothelial 
cells 16. Using a modified computational analysis pipeline 17, RNA sequencing data of 
ribo-minus RNA from HUVECs cultured under normoxic or hypoxic conditions was 
analysed. cZNF292, cAFF1, and cDENND4C were shown to be up-regulated by 
hypoxia. Silencing of cZNF292 inhibited cZNF292 expression and reduced tube 
formation and spheroid sprouting of endothelial cells in vitro. Since circRNAs were 
previously suggested to act as microRNA sponges 17, the authors also explored 
whether this mechanism of action accounts for the biological function of endothelial 
circRNAs, by merging the RNA sequencing data with Argonaute HITS-CLIP data. 
Here the majority of circRNAs were shown to not possess a microRNA binding site, 
and only a small number have more than one binding site, suggesting that the 
majority of circRNAs are not acting as miRNA sponges, although this requires further 
exploration. 
Cardiovascular aging-associated non-coding RNAs 
The role of aging associated non-coding RNAs has been recently reviewed 18. Here 
we focus on novel lncRNAs that were not covered in the aforementioned review. The 
hypoxia-sensitive nuclear-localised lncRNA Meg3 was induced highly in endothelial 
cells of aged mice in vivo compared to controls and its levels correlate with aging in 
human heart tissue 19. In vitro, Meg3 was increased in replicative senescent 
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HUVECs. Silencing of Meg3 using LNA gapmeRs induced angiogenic sprouting and 
proliferation and repressed senescence as evidenced by the reduction of SA-β-
galactosidase activity of endothelial cells in vitro. Conversely, lentiviral 
overexpression of Meg3 inhibited sprouting angiogenesis and cell cycle progression, 
although splicing isoforms of Meg3 show differential effects. In vivo, silencing of 
Meg3 in aged mice using gapmeRs in combination with hind limb ischemia 
significantly repressed Meg3 levels in the hind limb and increased recovery of 
perfusion compared to control mice. These results demonstrate that silencing Meg3 
may be a potential strategy to reduce endothelial senescence and increase 
regenerative angiogenesis. Of note, Meg3 is also expressed in other non-endothelial 
cells such as cardiac fibroblasts and its silencing was effective in reducing cardiac 
fibrosis showing importance of this lncRNA broadly as a potential target in the 
treatment of cardiovascular diseases 20.  
A novel approach for aged patients with cardiovascular diseases using non-coding 
RNAs as targets was recently presented.  Aging populations show higher incidences 
of myocardial infarction (MI) and heart failure (HF). With regards to miRNAs, miR-22 
was shown to be strongly increased during aging in murine and human hearts and 
was identified as an abundant and strong inhibitor of cardioprotective autophagy 21. 
Inhibition of miR-22 in aging cardiomyocytes activated autophagy and inhibited 
cellular hypertrophy. Pharmacological inhibition of miR-22 post-MI in older mice 
activated cardiac autophagy, prevented post-infarction remodeling, and improved 
cardiac function compared with control subjects. Interestingly, similar effects were 
less pronounced in younger mice with significantly lower cardiac miR-22 expression 
levels. In addition, circulating levels of miR-22 in 154 patients with systolic HF were 
highly associated with early mortality. Thus, miR-22 seems to be an important 
regulator of cardiac autophagy and a potential therapeutic target, especially in the 
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older myocardium. Clearly, targeting therapeutics to the aged or diseased 
myocardium in human is challenging and requires sophisticated delivery strategies to 
be developed.  
 
Non-coding RNAs in smooth muscle cell biology 
The expression and function of long non-coding RNA in smooth muscle cells remains 
relatively poorly defined. Aside from SENCR 10, a recent study identified  a single 
transcript (3 exons) lncRNA called SMILR (Smooth Muscle cell Induced LncRNA) 
that was activated following exposure of basal vSMC to pro-proliferative signals. 
Following exposure to a combination of platelet-derived growth factor and interleukin 
-1, SMILR was induced 22. Interestingly SMILR was localized both in the nuclear 
and cytoplasmic compartments, suggestive of differential modes of action within the 
cell. Further, an accurate lncRNA quantification assay for secretion from cells and 
human plasma samples was developed. Indeed, plasma levels of SMILR were 
elevated in patients with higher C-reactive protein levels compared to patients with 
lower levels, albeit in a small population sample set.  Using a siRNA approach, an 
anti-proliferative effect following efficient downregulation of SMILR was identified, 
with effects on the neighboring gene HAS2. Further, levels of SMILR were higher in 
patients with advanced atherosclerosis compared to stable patient samples, 
suggesting relevance of human disease. These studies clearly show the importance 
of lncRNA expression on function of vSMC. Since vSMC are centrally important in 
vascular health and disease, this suggests a much greater understanding of both 
required and essential lncRNA characteristics. Several questions remain regarding 
the function of SMILR. These include the mode of action with respect to vSMC 
proliferation. Further, how this is consistent across vascular beds and 
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vasculoproliferative diseases, as well as refining the therapeutic potential of SMILR 
inhibition to block proliferation. Notably, in the context of vein graft failure, an anti-
proliferative strategy would provide likely efficacy when considering the predominant 
role of vSMC in vein graft neointima formation.  Other studies have also 
demonstrated the importance of lncRNA in vSMC function 23, 24, consistent with the 
notion that they hold important regulatory potential in vascular health and disease. 
 
Non-coding RNAs in the control of mitrochondrial function and energy 
metabolism 
Recently, miRNAs emerged as central regulators of mitochondrial function and 
energy metabolism in diabetes, hypertension, ischemia, atherosclerosis and 
cardiotoxicity. Mitochondrial miRNAs –also mitomiRs- are enriched in those diseases. 
In diabetes mellitus, mitomiRs are enriched in spatially distinct compartments 25, 
whereas in hypertensive- hearts their expression differ in the early and later stage of 
heart failure 26. In general, miR-146a, -181c and -378 act as important therapeutic 
targets affecting mitochondrial function in cardiovascular diseases. MiR-146a was 
first reported to affect cardiac metabolism during peripartum cardiomyopathy 27. 
Uptake by cardiomyocytes of endothelial cell-released miR-146a decreased the 
metabolic activity of cardiomyocytes during pregnancy, with downregulation of Erbb4, 
Notch1 and Irak1. Inhibition of miR-146a is thereby protective. Its suppression is not 
only beneficial in peripartum cardiomyopathy, but also in pressure-overload induced 
cardiomyopathy 28, and in atherosclerosis 29. Inhibition of miR-146a in pressure 
overload –either with aortic banding or angiotensin-II infusion- blunted the cardiac 
hypertrophic response and protected against systolic dysfunction 29. MiR-146a 
decreased dihydrolipoyl succinyl transferase (DLST) levels, a rate-controlling enzyme 
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in the tricarboxyl acid (TCA) cycle in the failing heart, thereby impairing cardiac 
oxidative metabolism. Both fatty acid and glucose oxidation decreased upon 
pressure overload in wild type mice, but were preserved upon miR-146a inhibition. 
Increase of DLST upon loss of miR-146a helped to preserve these oxidative fluxes, 
protecting against maladaptive hypertrophy and dysfunction. As in peripartum 
cardiomyopathy 27 and in atherosclerosis 29, miR-146a seems to be mainly derived 
from endothelial cells.  In line, also in atherosclerosis, deficiency of miR-146a in 
those endothelial cells tempered the chronic inflammatory response to the 
atherogenic high fat diet, thereby protecting against atheroma formation 29.  MiR-
181c is another detrimental mitomiR involved in mitochondrial function. Its inhibition 
increases Bcl2, a key-player in mitochondrial apoptosis and morphology, and thereby 
protects against cardiomyocyte apoptosis in vitro 30. In doxorubicin-induced toxicity in 
vivo, miR-181c inhibition decreases the reactive oxygen species production and 
reduces basal mitochondrial respiration 31. In ischemic hearts, miR-181c targets 
mitochondrial COX1, and its deficiency thereby resulted in decreased infarct size, 
emphasizing the overall cardio-protective effect of miR-181c inhibition. Further, 
presence of miR-378 attenuated ischemia-induced apoptosis by inhibiting caspase-3 
expression in cardiac myocytes 32 and blunted cardiac hypertrophy and dysfunction 
upon cardiac overload by targeting Ras signaling 33. In the diabetic heart, antagomiR 
blockade of this mitomiR-378 increased ATP6 protein production and thereby also 
improved cardiac function 25. In a human infarct study, miR-378 modulated the 
proangiogenic capacity of CD34+ progenitor cells after myocardial infarction, with 
clear stimulatory effects on endothelial cells as confirmed in vitro and in vivo 34.   
In conclusion, diverse mitomiR modulate mitochondrial function in cardiovascular 
diseases caused by ischemia,  the metabolic syndrome –diabetes, hypertension and 
hyperlipidemia-,  and cardiotoxic agents. Whereas inhibition of the mitomiRs-146a is  
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beneficial in hypertensive and peripartum cardiomyopathy, and in atherosclerotic 
disease, and inhibtion of miR-181c in ischemic and toxic cardiomyopathy, the 
presence of miR-378 is needed to protect against cardiac dysfunction caused by 
ischemic injury and maladaptive hypertrophy.  
 
Circulating microRNAs as novel cardiovascular biomarkers 
Previous studies have highlighted the presence of endogenous circulating miRNAs 
that are not cell-associated. Zampetaki and colleagues have performed the first 
systematic analysis of circulating miRNAs in a large community-based study and 
revealed a diagnostic potential of miRNA changes associated with type 2 diabetes 
and cardiovascular disease 35, 36. In subsequent studies, it has become apparent that 
platelets have abundant amounts of miRNAs 37, and that circulating miRNAs reflect 
platelet activation 38, 39. As platelets are anucleate and do not perform transcription, it 
was initially thought that circulating miRNAs are unlikely to be platelet-derived. 
However, surprisingly many abundant plasma and serum miRNAs, including miRNAs 
like miR-126 that were previously thought to be endothelial specific, can originate 
from platelets 37-39. YRNAs is another species of circulating non-coding RNAs that is 
platelet-derived 39. There still remains a gap in our understanding of how changes in 
platelet biology relate to circulating miRNAs. In contrast, miR-122 is a liver-specific 
miRNA that is readily detectable in the circulation 40. Notably, circulating levels of 
miR-122 are strongly associated with the risk of developing metabolic syndrome 41. 
The presence of circulating tissue-derived miRNAs provides the possibility of a cross-
organ communication by miRNAs. 
 
 CVR-2018-115  
page 12 of 18 
Conclusion and Outlook 
The discovery of miRNAs and other non-coding RNAs such as lncRNAs and 
circRNAs that are involved in transcriptional and other functional regulation of the 
vasculature have transformed our understanding of biological processes and disease 
development especially in cardiovascular diseases. This might lead to new 
therapeutics and diagnostics. The non-coding RNAome offers promising 
opportunities for treating and assessing cardiovascular disease, but many obstacles 
still need to be overcome. A major point to address in therapeutic use of non-coding 
RNAs is to develop tailored drug delivery with e.g. heart specificity. Next to that, 
lncRNA and circRNAs are relatively new areas of research, thus it is paramount to 
better understand their biological function. 
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Figure Legends 
Figure 1. Non-coding RNAs as angiogenic therapeutic entry points. 
Enhancement or inhibition strategy can be followed for modulation of vascular non-
coding RNAs. Circular RNA, miRNA or long non-coding RNA are target structures for 
therapeutic intervention. Modulation of RNA subtypes triggers expression changes 
(up or down) of interacting effectors (e.g. proteins such as chromatin modifiers or 
ribosomal factors or different RNA species). Collectively cardiac vascularization is 
positively or negatively influenced dependent on the chosen non-coding RNA 
therapy. 
 
Figure 2. GATA2 as a central player for angiogenic non-coding RNAs (modified 
from 6). 
Besides the regulation of GATA2-dependent coding genes (e.g. ICAM1, VCAM1), 
endothelial transcription factor GATA2 directly controls transcription of miR-126 / 
miR-221 locus. Interestingly loss of GATA2 causes DNA hypomethylation thereby 
activating miR-221 expression. Next to that, GATA2 repression lowers miR-126 
expression levels causing an upregulation of anti-angiogenic factors. Overall, 
downstream modulation leads to anti-angiogenic outcome and imbalanced 
endothelial cell biology. 
 
Table 1. Non-coding RNA associated biomarker studies 
 
Non-coding RNA Disease association Study reference 
miR-126 type 2 diabetes 35 
miR-126, miR-197, miR-
223 
myocardial infarction 36 
miR-126, miR-150, miR-
191, miR-223 
atherosclerosis 38 
YRNA platelet reactivity 39 
miR-122 Metabolic syndrome 
development and type 2 
diabetes 
41 
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